Thursday Panel Vote on Janssen Diabetes Drug Comes as First-Mover Advantage Is in Doubt

An FDA advisory panel’s upcoming vote on Janssen’s Type 2 diabetes drug canagliflozin may determine whether the company beats Eli Lilly and Boehringer Ingelheim’s (BI) empagliflozin to market. The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee is set to discuss the drug, known as Inkovana, on Thursday.
Drug Industry Daily